You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective,Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage

    SBC: NEUROP, INC.            Topic: 102

    Abstract Subarachnoid hemorrhageSAHremains a serious source of neurological morbiditywith approximatelycases reported in the US each yearDespite advances in treating the initial and subsequent bleedspost surgical clipping of the aneurysm is associated with a significant risk of delayed cerebral ischemiaDCIThese events typically occur within the firstdays after aneurysmal rupture and DCI remains th ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Noninvasive Contrast Enhanced Early Detection of Melanoma Liver Metastasis

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: 102

    Abstract The liver is the most common organ for metastasis of various cancersincluding pancreaticovariancolorectalgastric cancers and melanomaUveal melanoma metastasizes inof patients and upon metastasis targets the liver inof these casesThe most common primary malignant liver cancer worldwide is hepatocellular carcinomaHCCThe use of blind liver biopsy as a diagnostic tool for liver cancer has man ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. IND enabling studies for a personalized immunotherapy for triple negative breast cancer

    SBC: METACLIPSE THERAPEUTICS CORPORATION            Topic: NCI

    Abstract The worldwide incidence of breast cancer ismillionTriple negative breast cancersTNBCaccount forof total breast cancer casesworldwideAnnuallyovernew cases of TNBC are diagnosed in the US aloneThe treatment options for TNBC patients are limitedTriple negative breast cancerTNBCincludes breast cancers that lack estrogen receptorprogesterone receptorand HERproteinsLack of known targets and pat ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Micro Patterned Intraocular Lens Membrane for Reducing Incidence of PCO

    SBC: CLEARSIGHT, LLC            Topic: N

    AbstractThe exponential increase of diabetics and the elderly in the U Shas more than tripled the number of cataract surgeries performed in just two decadesAs many as half of these surgeries will lead to posterior capsular opacificationPCOwhich requires follow up Nd YAG laser capsulotomy surgeryWithout this additional procedurepatients can suffer permanent vision loss and disabilityIn many countri ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Tough Talks: A Disclosure Intervention for HIV+ YMSM

    SBC: VIRTUALLY BETTER INC            Topic: 105

    PROJECT SUMMARY Men who have sex with menMSMaccount for nearly two thirds all of new HIV infections in the United StatesUSand young MSMYMSMare the only risk group experiencing a significant increase in HIV incidenceAmong youthpercent report not disclosing to their first time sex partnersDisclosing of one s HIV status is important for accessing support which can lead to improved medication adherenc ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity

    SBC: Colorado Research Partners LLC            Topic: 300

    Our goal is to develop a firstin class therapeutic agent that directly blocks the metabolism of fructosea key component in sugarIntake of sugarsucroseand high fructose corn syrupHFCSinduces metabolic syndrome and diabetes in laboratory animals and are strongly associated with obesity and diabetes in humansBoth sucrose and HFCS contain fructosewhich stimulates food intake by inducing leptin resista ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Site-specific O-GlcNAc Antibodies for Epigenetic Research

    SBC: GlycoScientific, L.L.C.            Topic: 300

    Project SummaryO glycosylation of nuclear and cytoplasmic proteins by a singleN acetyl D glucosamine moietyOGlcNAcis a common post translational modification that is highly dynamic and fluctuates in response to cellular stimuliThis type of glycosylation has been found on approximately a thousand human proteins to dateand is thought to be nearly as wide spread and abundant as protein phosphorylatio ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Miniature and Reliale Chemical Sensors for Cell Phones

    SBC: SYNKERA TECHNOLOGIES INC            Topic: HSB081002

    In the event of a terrorist attack, the ability to measure the extent and location of the attack and rapidly notify first responders will be critical to saving lives. If the widespread use of cell phones could be harnessed with an ability to detect chemical threats and immediately notify authorities of the scope and location of the attack, public safety would be significantly enhanced. Synkera pro ...

    SBIR Phase II 2009 Department of Homeland Security
  9. Reagents specific for all N-glycans

    SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC            Topic: 400

    PROJECT SUMMARY Glycans have several distinct properties that make them excellent targets for disease biomarkersFirstlytheir location glycans on cell surfaces makes them the first point of contact for cellular interactionsand thus they are crucial in the control of normal metabolic processesSecondlycell surface molecules are also strategically exposed for surveillance by the immune system allowing ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Human Neural Cell Exosomes as a therapeutic treatment for stroke

    SBC: Aruna Biomedical, Inc.            Topic: 105

    Project Summary More than drugs have failed in stroke clinical trials an unprecedented rate thought to be attributed to two major factors most therapeutics focus on a single secondary injury mechanism and testing in rodent models alone may not be adequate for predicting which treatment is going to be successful We will combine two unique enabling technologies to address these caveats ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government